Free tool
FAERS Monitor: Xigduo Xr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205649 or its brand name (Xigduo Xr, Dapagliflozin, Metformin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
3,503
Serious
2,578
74% of reports
Hospitalization
1,171
Death reported
227
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea233
- blood glucose increased232
- diarrhoea179
- vomiting179
- weight decreased178
- diabetic ketoacidosis177
- off label use176
- fatigue146
- drug ineffective133
- death129
- dizziness110
- acute kidney injury109
- asthenia101
- ketoacidosis98
- headache89
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2015 | 156 |
| 2016 | 239 |
| 2017 | 239 |
| 2018 | 241 |
| 2019 | 374 |
| 2020 | 329 |
| 2021 | 311 |
| 2022 | 285 |
| 2023 | 343 |
| 2024 | 397 |
| 2025 | 317 |
| 2026 | 271 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,656 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ketoacidosisSignal | 98 | 79.7 | 65.4 | 7,437 |
| diabetic ketoacidosisSignal | 177 | 44.6 | 38.6 | 7,448 |
| blood glucose increasedSignal | 232 | 7.4 | 6.5 | 1,288 |
| acute kidney injurySignal | 109 | 4.3 | 3.6 | 272 |
| weight decreasedSignal | 178 | 3.8 | 3.3 | 374 |
| vomitingSignal | 179 | 2.3 | 2.0 | 131 |
| nausea | 233 | 1.8 | 1.6 | 80 |
| diarrhoea | 179 | 1.7 | 1.4 | 48 |
| asthenia | 101 | 1.6 | 1.3 | 23 |
| dizziness | 110 | 1.3 | 1.1 | 9 |
| off label use | 176 | 1.2 | 1.0 | 6 |
| fatigue | 146 | 1.1 | 1.0 | 2 |
| death | 129 | 0.9 | 0.8 | 1 |
| headache | 89 | 0.9 | 0.7 | 2 |
| drug ineffective | 133 | 0.6 | 0.5 | 36 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.